Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US-2024352036-A1 · Oct 24, 2024 · US
Anticancer maytansinoids with two fused macrocyclic rings
US2016289244A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016289244-A1 |
| Application number | US-201415100985-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 2, 2014 |
| Priority date | Dec 2, 2013 |
| Publication date | Oct 6, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides maytansinoids having improved tumor inhibition activity, in particular, the present invention provides a method of treatment of cancer, in particular colon cancer, using maytansinoid compounds having two fused macrocyclic rings.
First claim
Opening claim text (preview).
1 . A compound having a structure of: wherein R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen and an group having 1 to 6 carbon atoms. 2 . The compound of claim 1 , wherein the compound having a structure of 3 . A compound having a structure of: wherein R is a substituted or non-substituted chain alkyl group having at least 3 carbon atoms and no more than 8 carbon atoms. 4 . The compound of claim 3 , wherein R is CH 2 CH 2 CH 3 . 5 . A method of treating cancer, comprising: administering an effective dose of the compound according to claim 1 daily. 6 . The method according to claim 5 , wherein the effective dosage is at least 1.6 μg/kg per patient body weight. 7 . The method according to claim 5 , wherein the effective dosage is about 3.2 μg/kg per patient body weight. 8 . The method according to claim 5 , wherein the effective dosage is about 0.004 mg/kg per patient body weight. 9 . The method according to claim 5 , wherein the effective dosage is about 20 μg/kg per patient body weight. 10 . The method according to claim 5 , wherein the effective dosage is about 40 μg/kg per patient body weight. 11 . The method according to claim 5 , wherein the effective dosage is about 0.05 mg/kg per patient body weight. 12 . The method according to claim 5 , wherein the cancer treated is colon carcinoma. 13 . The method according to claim 5 , wherein the cancer treated is oral epidermoid carcinoma. 14 . The method according to claim 5 , wherein the cancer treated is promyelocytic leukemia. 15 . The method according to claim 5 , wherein the cancer treated is prostate carcinoma. 16 . The method according to claim 5 , wherein the cancer treated is breast carcinoma. 17 . The method accordion to claim 5 , wherein the cancer treated is lure carcinoma. 18 . A method of treating cancer comprising administering an effective dose of the compound according to claim 3 daily.
Assignees
Inventors
Classifications
- C07D498/22Primary
in which the condensed system contains four or more hetero rings · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016289244A1 cover?
- This invention provides maytansinoids having improved tumor inhibition activity, in particular, the present invention provides a method of treatment of cancer, in particular colon cancer, using maytansinoid compounds having two fused macrocyclic rings.
- Who is the assignee on this patent?
- Univ Hong Kong Baptist Univ, The Board Of Trustees Of The Univ Of Iilinois
- What technology area does this patent fall under?
- Primary CPC classification C07D498/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Oct 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).